Insitro IPO

Insitro combines machine learning with experimental biology to discover and develop new medicines more efficiently than traditional pharmaceutical approaches. Founded by former Google executive Daphne Koller, the company uses AI models to predict how potential drugs will behave in human patients, potentially reducing the time and cost of bringing new treatments to market.

The company operates its own wet lab facilities where it generates high-quality biological data to train its machine learning models, creating a feedback loop between computational predictions and experimental validation. Insitro has established partnerships with major pharmaceutical companies including Roche and Bristol Myers Squibb, focusing on areas such as liver disease and neurodegeneration. Their approach represents a new paradigm in drug discovery where AI doesn't just assist traditional methods but fundamentally reimagines how pharmaceutical research is conducted.